PharmaShots | Incisive News in 3 Shots

Subscribe Now

regeneron

Regeneron Enters a ~$3B Multi-Year Manufacturing Agreement with FUJIFILM Diosynth Biotechnologies

Regeneron Enters a ~$3B Multi-Year Manufacturing Agreement with FUJIFILM Diosynth Biotechnologies

April 23, 2025

Regeneron and Sanofi Report the US FDA’s Approval of Dupixent for Chronic Spontaneous Urticaria

Regeneron and Sanofi Report the US FDA’s Approval of Dupixent for Chronic Spontaneous Urticaria

April 21, 2025

The US FDA Accepts sBLA Priority Review for Regeneron's EYLEA HD in Macular Edema Following RVO and Monthly Dosing In Approved Indications

The US FDA Accepts sBLA Priority Review for Regeneron's EYLEA HD in Macular Edema Following RVO and Monthly Dosing In Approved Ind...

April 18, 2025

The CHMP Recommends Conditional Approval of Regeneron’s Linvoseltamab to Treat R/R Multiple Myeloma (MM)

The CHMP Recommends Conditional Approval of Regeneron’s Linvoseltamab to Treat R/R Multiple Myeloma (MM)

March 3, 2025

Regeneron Presents P-I/II (CHORD) Trial Data of DB-OTO for Profound Genetic Hearing Loss at Association for Research in Otolaryngology 2025

Regeneron Presents P-I/II (CHORD) Trial Data of DB-OTO for Profound Genetic Hearing Loss at Association for Research in Otolaryngo...

February 25, 2025

Regeneron and Sanofi Report the US FDA’s sBLA Acceptance for Dupixent to Treat Bullous Pemphigoid (BP)

Regeneron and Sanofi Report the US FDA’s sBLA Acceptance for Dupixent to Treat Bullous Pemphigoid (BP)

February 18, 2025

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us